SEATTLE, June 01, 2018 (GLOBE NEWSWIRE) --
In a release issued yesterday under the same headline by CFN Media, please be advised that a quote has
been removed from the first paragraph. Additionally, the stock exchange for Emblem Corp. in the ninth paragraph should be TSX-V
rather CSE, and the reference in that same paragraph to "five projects" should simply read "projects". The corrected
release follows.
Canntab Brings Pharma Standards to Medical Cannabis -- CFN Media
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry,
today announced publication of an article covering CannTab Therapeutics Inc. (CSE:PILL) (CNSX:PILL) (PILL.CN) and its plan to make medical
cannabis more reliable with its proprietary, patent-pending, extended-release tablets that offer a reliable and uniform dosage over
several hours. By making medical cannabis more like traditional pharmaceuticals, these products should be more readily prescribed
by doctors than the smoking of cannabis flower.
According to Arcview Market Research the North American cannabis industry is expected to grow more than
three-fold from $6.57 billion in 2016 to $20.2 billion by 2021. The legalization of adult-use cannabis by the government of
Canada will open the door to a much wider market in Canada, where legalization is currently anticipated for the summer of 2018.
There are signs that U.S. lawmakers are ready to further legitimize medical cannabis by potentially removing marijuana from the
list of Schedule I Controlled Substances.
As with any rapidly expanding market, there have been many growing pains along the way. Canadian licensed producers have
been plagued with recalls for contaminated products due to the lack of testing standards,
while inaccurate labeling has hurt consumers’ trust in the regulated medical cannabis space. Many
medical cannabis companies and doctors also struggle with dosing issues given the unique nature of cannabis and the lack of robust
clinical trial data.
A Lack of Standards
Cannabis bioavailability is a significant issue facing the medical community. In a 2009 study, researchers found that cannabinoid bioavailability ranged from two to 56 percent for
inhaled cannabis smoke and from four to 20 percent for orally consumed cannabis products. These wide ranges make it difficult for
physicians to anticipate how cannabis will affect a patient, which makes them less likely to prescribe cannabis-based
medications.
The reality is that cannabis affects different people in different ways due to its nature. For one, cannabis contains hundreds
of cannabinoids that interact in ways that scientists are only starting to understand. The metabolism of cannabinoids also depends
on an individual’s body type since it’s a fat-soluble and subject to first-pass liver metabolism. And finally, regular users may
build up a tolerance and require higher dosing than casual or new users.
Many companies have started to develop cannabinoid delivery mechanisms designed to improve bioavailability, but it’s a
challenging task that requires extensive research and development. In addition, many of these delivery mechanisms may be unfamiliar
to patients that are accustomed to taking pharmaceutical drugs in pill form. The most promising companies are those that are
closely adhering to pharmaceutical standards..
Canntab’s Unique Solutions
Canntab Therapeutics aims to develop advanced pharmaceutical-grade cannabis formulations. Using its in-house technology, the
company delivers standardized medical cannabis extract from selective strains in a variety of extended-release/sustained release
pharmaceutical dosages for therapeutic use. As the company likes to say, it puts the “medical” into “medical cannabis” by bringing
pharmaceutical standards to the industry.
The company’s proprietary, patent-pending Canntab XR Tablets provide an extended release and uniform dosing of cannabis over an
extended number of hours. Doctors or patients can access a wide range of THC/CBD variations to effectively manage any ailment,
while taking advantage of the discreet tablet format that easily fits into any patient’s lifestyle. These tablets are also highly
reliable and made to pharmaceutical-grade standards.
In late-2017, the company signed a licensing deal with Emblem Corp. (TSX-V:EMC), a Canadian licensed producer of medical
cannabis, to market and develop products in Canada, and closed a joint venture deal with Queensland Bauxite to make its products
available in Australia and Asia. Recently, Health Canada approved R&D activities for Canntab’s oral sustained release
formulations of cannabinoids, which paves the way for these new products.
“We are thrilled that Health Canada has approved the research and development phase of our partnership with Canntab,” said
Emblem President and CEO Nick Dean in the press release announcing the approval. “The introduction of Canntab’s sustained release
formulation presents a significant growth opportunity for Emblem that is expected to begin in 2019.”
In addition to that licensing deal, the company announced a joint venture with Queensland Bauxite (ASX:QBL) to develop and
market its patented tablets. The new venture will compete with MMJ Phytotech, which is the only company that’s currently importing
a cannabis-containing pill in partnership with the Swiss drugmaker, Satipharm. Queensland Bauxite is confident that the
standardized dosing will convince doctors and regulators to support the product as a way to prescribe measurable doses of
cannabis.
Management is also working to close a deal to co-locate with FV Pharma to produce and distribute its products in Canada and
around the world.
Looking Ahead
CannTab Therapeutics Inc. (CSE:PILL) represents a compelling investment opportunity within the burgeoning cannabis industry. By
addressing key issues with bioavailability and dosing, the company’s products should appeal to traditional doctors and patients
looking for reliable solutions to meet their medical needs. Recreational users will be able to benefit from a consistent experience
as well.
For more information, visit the Company’s Website at: Canntab Therapeutics Inc.
Please follow the link to read the full article: http://www.cannabisfn.com/canntab-brings-pharma-standards-medical-cannabis/
About CFN Media
CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps
companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in
the US and Canada have relied on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your
iPhone: http://www.cannabisfn.com
Disclaimer
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own
independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid
advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm
enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other
editorials for advertising such companies. We are not an independent news media provider. We make no warranty or
representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly
and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As
such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted.
CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along
with financial and corporate news.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create
awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
Contact:
Frank Lane
206.369.7050
flane@cannabisfn.com
